Clinical Trial Update: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study comparing CA102N plus TAS-102 to bevacizumab plus TAS-102 in relapsed/refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CA102N
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Holy Stone Healthcare Co., Ltd | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN